HEALTHCARE COSTS IN WOMEN WITH HR+/HER2-METASTATIC BREAST CANCER TREATED WITH CDK4/6 INHIBITORS

被引：0
作者：
Burne, R. [1 ]
Balu, S. [2 ]
Guerin, A. [1 ]
Liang, Y. [1 ]
Schloessmann, R. [3 ]
Bungay, R. [1 ]
Paul, M. L. [2 ]
机构：
[1] Anal Grp Inc, Montreal, PQ, Canada
[2] Novartis Pharmaceut, E Hanover, NJ USA
[3] Anal Grp Inc, Chicago, IL USA
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN120
引用
收藏
页码：S44 / S44
页数：1
相关论文
共 50 条
  • [21] Analyzing the changes in the HR+/HER2-metastatic breast cancer (mBC) landscape since the arrival of CDK4/6 inhibitors with machine learning and visual analytics
    Meade, D.
    Alford, S. Hensley
    Mahatma, S.
    Malangone-Monaco, E.
    Boulanger, L.
    Tkacz, J.
    Turner, S. J.
    Chen, S.
    Manson, S.
    Mejia, S.
    Buleje, I.
    Madan, P.
    Kim, G.
    Fowler, R.
    Basar, A.
    CANCER RESEARCH, 2019, 79 (04)
  • [22] CDK4/6 inhibitors combined with fulvestrant for HR+/HER2- advanced breast cancer
    Zhang, Jie
    Hao, Chunfang
    TRANSLATIONAL BREAST CANCER RESEARCH, 2022, 3
  • [23] Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2-metastatic breast cancer: A closer look at nonmedication expenses
    Pilehvari, Asal
    You, Wen
    Kimmick, Gretchen Genevieve
    Bonilla, Gloribel
    Anderson, Roger
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] Therapy of HR+/HER2-advanced Breast Cancer CDK4/6 Inhibitors: Studies, Everyday Healthcare and Guidelines
    Ruedesheim, Sabine M.
    BREAST CARE, 2021, 16 (03)
  • [25] Indirect Treatment Comparison of First-Line CDK4/6-Inhibitors in Post-Menopausal Patients with HR+/HER2-Metastatic Breast Cancer
    Zhao, Joseph J.
    Fong, Khi Yung
    Chan, Yiong Huak
    Tey, Jeremy
    Dawood, Shaheenah
    Lee, Soo Chin
    Finn, Richard S.
    Sundar, Raghav
    Lim, Joline S. J.
    CANCERS, 2023, 15 (18)
  • [26] Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2-metastatic breast cancer
    Zhao, Joseph J.
    Fong, Khi Yung
    Chan, Yiong Huak
    Tey, Jeremy Chee Seong
    Dawood, Shaheenah S.
    Lee, Soo-Chin
    Finn, Richard S.
    Sundar, Raghav
    Lim, Joline S. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [27] Optimizing CDK4/6 inhibitors in advanced HR+/HER2-breast cancer: A personalized approach
    Fontanella, Caterina
    Giorgi, Carlo Alberto
    Russo, Stefania
    Angelini, Silvia
    Nicolardi, Linda
    Giarratano, Tommaso
    Frezzini, Simona
    Pestrin, Marta
    Palleschi, Dario
    Bolzonello, Silvia
    Parolin, Veronica
    Haspinger, Eva R.
    De Rossi, Costanza
    Greco, Filippo
    Gerratana, Lorenzo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2022, 180
  • [28] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    MODERN PATHOLOGY, 2022, 35 (SUPPL 2) : 136 - 138
  • [29] CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer: Clinico-Pathological Analysis for Determinants of Response
    Maruthi, Vijaya Kadam
    Schultz, Emily
    Knudsen, Erik
    Witkiewicz, Agnieszka
    Hamilton, Deanna
    LABORATORY INVESTIGATION, 2022, 102 (SUPPL 1) : 136 - 138
  • [30] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08) : 646 - 654
12345